Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Unichem Laboratories has informed that it has enclosed the press release on 19th February 2021 pertaining to receipt of ANDA approval from United States Food and Drug Administration (USFDA) for Unichem’s Apremilast Tablets, 10 mg, 20 mg and 30 mg.
The above information is a part of company’s filings submitted to BSE.